drugset / Trial / NCT00951054
A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer
RandomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether NK012 is safe and effective in the treatment of advanced and metastatic triple negative breast cancer.
Timeline
- Start
- 2009-02
- Primary completion
- 2014-12
- Completion
- 2015-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 7-ethyl-10-hydroxy Camptothecin | Small molecule | 18 mg/m2 | Intravenous |
| Subject | 7-ethyl-10-hydroxy Camptothecin | Small molecule | 28 mg/m2 | Intravenous |